Clinical trial recruitment platform SubjectWell scores $35M

Must read

SubjectWell, a patient recruitment platform for clinical trials, announced it raised $35 million in a Series B funding round led by Asset Management Ventures.

Other participants in the round include Bertelsmann and existing investors Healthy Ventures, Windham Venture Partners and Geekdom Fund.

According to Crunchbase, the Texas-based company has raised $46.8 million over seven funding rounds.


The new investment round will help SubjectWell accelerate its clinical trial-recruitment work, fund its awareness initiatives regarding post-approval treatments and help expand the company’s support of cancer research. 

“SubjectWell’s platform aggregates patients across scores of media channels, thus creating an unprecedented pool of consented patients – and can do so at scale. We’re proud to partner with SubjectWell and are excited to support the continued development of the first audience engagement platform for healthcare,” Thorsten Wirkes, senior vice president with Bertelsmann Investments, said in a statement.


Numerous companies are finding ways to streamline the clinical trial participation process for participants. 

In May, decentralized clinical trial-company Curebase, which offers patients a way to find and enroll in clinical trials, sign consent forms, access telemedicine and schedule home visits, scored $40 million in a Series B round. The company also provides a site-facing platform assisting with participant recruitment and prescreening. 

A month later, decentralized clinical trial company THREAD announced it acquired CureClick, a platform for recruiting trial participants that aims to enroll participants in decentralized clinical trials more easily.

Overseas, Australian startup HealthMatch, a platform for matching patients with clinical trials, closed a Series C funding round of A$10 million ($6.8 million) that would help the company expand its team and its platform’s reach across the U.S.

Source link

- Advertisement -spot_img

More articles


Please enter your comment!
Please enter your name here

- Advertisement -spot_img

Latest article